About: Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
Sector: Healthcare
Industry: Biotechnology
Latest price: $10.71 (-6.22%)
KLRA NASDAQ Kailera Therapeutics, Inc. Common Stock
Kailera Therapeutics, Inc. Common Stock share price
KLRA price activity
Último preço
$ 10,710
Variação (24h)
-0,71 USD (-6,22%)
Volume
76.19K
Volume (média 4 sem.)
-
Abertura
$ 11,39
Variação do dia
$ 10,71 - $ 11,75
Fechamento anterior
$ 11,42
Último negócio
01 Oct, 2:01 pm GMT+0
Atrasado
01 Oct, 2:01 pm GMT+0
KLRA price performance
Atrasado
01 Oct, 2:01 pm GMT+0
quote.marketSignals